A TLR7 agonist enhances the antitumor efficacy of obinutuzumab in murine lymphoma models via NK cells and CD4 T cells.
PubMed 文献 · Leukemia · 2017-07-28
This corrects the article DOI: 10.1038/leu.2016.352.
原文
This corrects the article DOI: 10.1038/leu.2016.352.
来源:Leukemia,查看原文。版权归原作者所有。
引用
- Cheadle EJ, Lipowska-Bhalla G, Dovedi SJ, et al. A TLR7 agonist enhances the antitumor efficacy of obinutuzumab in murine lymphoma models via NK cells and CD4 T cells. Leukemia. 2017. PMID: 28751765. doi:10.1038/leu.2017.218
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。